| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441781 | European Journal of Cancer | 2015 | 8 Pages |
Abstract
Although there was no significant difference in overall response rates to 131I-MIBG between patients with relapsed versusrefractory neuroblastoma, patients with prior relapse had higher rates of progressive disease and had lower 2-year overall survival after 131I-MIBG compared to patients with refractory disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Margaret J. Zhou, Michelle Y. Doral, Steven G. DuBois, Judith G. Villablanca, Gregory A. Yanik, Katherine K. Matthay,